8-K: Radnostix Terminates DUF6 Plant Sale, Recalls Capsules

Radnostix, Inc. announced the mutual termination of its Asset Purchase Agreement for the DUF6 Plant and initiated a voluntary recall of certain Dibasic Sodium Phosphate Capsules.

Summary

• Radnostix, Inc. mutually terminated the Asset Purchase Agreement (APA) with American Fuel Resources, LLC (AFR) for its depleted uranium deconversion and fluorine extraction plant (DUF6 Plant).
• AFR was unable to make the final payment of $12,450,000 by the March 31, 2026 deadline and requested a one-year extension.
• Radnostix decided to terminate the agreement, believing the DUF6 assets have appreciated in value due to a resurgence in nuclear energy projects and had low confidence in AFR's ability to secure funding.
• AFR had previously made non-refundable payments totaling $170,000 ($50,000 prepayment and $120,000 in NRC Extension Fees).
• The termination means Radnostix will not receive the $12,450,000 balance, will not recognize a gain on sale, and will not use proceeds to repay long-term notes, impacting previously anticipated financial and operational results.
• Radnostix initiated a voluntary recall of specific lots of Dibasic Sodium Phosphate Capsules, manufactured between 2022 and 2025 and shipped from August 19, 2024, to February 17, 2026, due to being out of specification on final capsule weight.
• The recall is expected to result in a $75,000 charge to Q4 2025 results for inventory write-off, a $50,000 charge to Q1 2026 for customer refunds, and additional costs of approximately $75,000 for new inventory in 2026.
• Lost revenue from the recall is estimated at $25,000 to $75,000 per week, with the impact not expected to extend beyond Q2 2026.
• The company's primary product, Generic Sodium Iodide I-131, was not affected by the recall.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but predominantly negative development. While retaining potentially appreciating assets is a long-term positive, the immediate loss of a significant cash payment and the financial impact of a product recall create near-term headwinds and uncertainty.

Positives

• Regained control of DUF6 assets, which are believed to have appreciated in value due to a resurgence in large-scale nuclear energy projects and domestic uranium enrichment initiatives.
• Retained $170,000 in non-refundable payments from AFR.
• The company's core product, Generic Sodium Iodide I-131, was not impacted by the product recall.

Negatives

• Lost the anticipated $12,450,000 final payment from the APA.
• Will not recognize a gain on the sale of assets as previously expected.
• Will not use proceeds from the sale to repay various long-term notes.
• Will not realize previously anticipated positive impacts on cash, assets, liabilities, operating costs, or future financing flexibility from the APA.
• Incurring financial charges related to the voluntary product recall, including a $75,000 write-off for Q4 2025, $50,000 for Q1 2026 refunds, and an estimated $75,000 for new inventory in 2026.
• Experiencing lost revenue estimated at $25,000 to $75,000 per week due to the recall.

Risks

• Actual results could differ materially from management's expectations, plans, or projections regarding the financial impact of the APA termination and the product recall.
• Uncertainties and other factors could cause actual results, performance, or achievements to be materially different from any future results expressed or implied by forward-looking statements.
• The total cost and materiality of the voluntary recall are still being ascertained, with potential for additional costs beyond current estimates.
• The company's ability to successfully evaluate and monetize the DUF6 assets in the future is subject to market conditions and strategic execution.

Future Outlook

The company will evaluate all possible options for the DUF6 assets, believing they have appreciated in value due to a resurgence in large-scale nuclear energy projects. The financial impact from the product recall is expected not to extend beyond the second quarter of 2026, and the company does not anticipate a material impact on its ability to provide Generic Sodium Iodide I-131 or practitioners' ability to service patients.

Management Comments

• "With the resurgence in large scale nuclear energy projects, including several domestic uranium enrichment initiatives, we believe these assets have meaningful value to our shareholders and the fuel cycle industry as a whole."
• "I want to thank AFR for their persistence and efforts in trying to close this deal and their transparency at the end."
• "We look forward to exploring all our options for the DUF6 assets over the coming months."

Industry Context

StockSavvy.ai notes that the termination of the DUF6 Plant sale comes at a time when the nuclear energy sector is experiencing a resurgence, driven by large-scale projects and domestic uranium enrichment initiatives. This broader industry trend suggests that Radnostix's decision to retain the DUF6 assets could be strategically sound, positioning the company to potentially capitalize on increased demand and higher valuations for such assets in the future.

Stakeholder Impact

• Shareholders: Will not receive the anticipated $12.45 million from the sale, but retain ownership of assets believed to have appreciated in value. Will bear the costs and lost revenue from the product recall.
• Customers (Pharmacies, Clinics, Veterinarians): Affected by the voluntary recall of Dibasic Sodium Phosphate Capsules, requiring them to manage recalled inventory.
• Patients: While the main product (Sodium Iodide I-131) is not impacted, the recall of an accompanying capsule could cause minor disruption or inconvenience.
• Creditors: The company will not use the anticipated sale proceeds to repay various long-term notes, potentially impacting repayment schedules or liquidity.

Next Steps

• Radnostix will evaluate all possible options for the DUF6 assets over the coming months.
• More details on the potential financial impact of the product recall will be provided when the company reports its fourth-quarter results, or sooner if deemed material.

Key Dates

Recommendation

The termination of the APA removes a significant cash inflow and expected gain, which is a negative. However, the company's rationale for retaining the DUF6 assets, citing a resurgence in nuclear energy, suggests potential long-term value. The product recall, while incurring immediate costs and lost revenue, is stated to be short-term and not impacting the core product. Given these offsetting factors and the uncertainty around the future monetization of the DUF6 assets, a "hold" recommendation is appropriate for investors to await further clarity on the DUF6 strategy and the full financial impact of the recall.

Keywords

Radnostix, DUF6 Plant, Asset Purchase Agreement, Nuclear Energy, Product Recall, Radioisotopes, Sodium Iodide I-131, SEC Filing, RNX, International Isotopes